Rapid Micro Biosystems Stock (NASDAQ:RPID)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.00

52W Range

$0.58 - $1.34

50D Avg

$1.04

200D Avg

$0.89

Market Cap

$38.73M

Avg Vol (3M)

$66.42K

Beta

1.08

Div Yield

-

RPID Company Profile


Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

193

IPO Date

Jul 15, 2021

Website

RPID Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Service$7.94M$6.08M-
Product$20.06M$11.06M-
Government Contract---
Product and service revenue - non-recurring--$13.82M
Non-commercial revenue - non-recurring--$1.59M
Product and service revenue - recurring--$7.82M

Fiscal year ends in Dec 23 | Currency in USD

RPID Financial Summary


Dec 23Dec 22Dec 21
Revenue$22.52M$17.13M$23.23M
Operating Income$-56.56M$-63.22M$-47.23M
Net Income$-52.47M$-60.81M$-73.52M
EBITDA$-56.56M$-63.22M$-46.51M
Basic EPS-$-1.43$-3.72
Diluted EPS-$-1.43$-3.72

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 01, 24 | 12:45 PM
Q2 24Aug 02, 24 | 1:10 PM
Q1 24May 03, 24 | 10:15 AM

Peer Comparison


TickerCompany
OFIXOrthofix Medical Inc.
LUNGPulmonx Corporation
TIVCTivic Health Systems, Inc.
SRDXSurmodics, Inc.
LIVNLivaNova PLC
KIDSOrthoPediatrics Corp.
AIMDAinos, Inc.
LNSRLENSAR, Inc.
IRIXIRIDEX Corporation
BVSBioventus Inc.
AXGNAxoGen, Inc.
BBLGBone Biologics Corporation
BJDXBluejay Diagnostics, Inc.
OWLTOwlet, Inc.
RXSTRxSight, Inc.
VVOSVivos Therapeutics, Inc.